Inlyta

What is Inlyta?

Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types. It was approved by the U.S. Food and Drug Administration after showing a modest increase in progression-free survival, though there have been reports of fatal adverse effects.

Questions and answers on "Inlyta"

I was placed on the oral chemotherapy drug Inlyta in early September 2013 and began developing symptoms of TMJD shortly thereafter. I am also...

doctor1 MD

thanks for your query,
the main cause for TMJ disorder is stress, for that reason u might have been put on antianxiety drugs..so you need to take...

Read Full Thread   Ask a Doctor Now

Recent questions on  Inlyta

doctor1 MD

I was placed on the oral chemotherapy drug Inlyta in early September 2013 and began developing symptoms of TMJD shortly thereafter. I am also...

Ask Question
Doctor Image
MD

Hi, I am Dr. Andrew Rynne (Family Physician). I will be guiding you through the process. Please write your question below.

Related Disease & Conditions
Related Drugs/Medications
Related Treatment/Therapy
Related Medical Topics